Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024338403> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W2024338403 endingPage "9" @default.
- W2024338403 startingPage "3" @default.
- W2024338403 abstract "La análogos de insulina de acción rápida (AIAR; aspart, lispro, glulisina) presentan un perfil farmacocinético más parecido a la secreción fisiológica de insulina que la insulina regular humana, con un mejor control de la glucemia posprandial y menor riesgo de hipoglucemia. Aunque, en general, se admite que los AIAR presentan una eficacia y seguridad similares, sus diferencias en la estructura molecular y formulación hacen que su estabilidad fisicoquímica sea distinta. Aspart ha demostrado tener mayor estabilidad molecular, menor tendencia a la agregación y formación de fibrillas insolubles de insulina y, en consecuencia, un menor riesgo de oclusión de catéter en usuarios de bombas de insulina. Por ello, aspart es el único AIAR aprobado para ser usado hasta 6 días en perfusión subcutánea continua de insulina (ISCI). Además, aspart ha sido evaluado en todo tipo de pacientes y ha sido aprobado para ser utilizado en pacientes pediátricos mayores de 2 años y también, específicamente, en aquellos en tratamiento con ISCI. Rapid-acting insulin analogues (RAIA) – aspart, lispro, glulisine – have a more similar pharmacokinetic profile to physiological insulin secretion than human regular insulin, improving control of postprandial hyperglycemia and reducing the risk of hypoglycemia. Although it is generally accepted that the efficacy and safety of RAIA are similar, their differences in molecular structure and formulation lead to distinct physical-chemical stability. Aspart has been demonstrated to have greater molecular stability and a lower tendency to aggregation and formation of insoluble insulin fibrils and, consequently, a lower risk of catheter occlusion in insulin pump users. Therefore, aspart is the only RAIA approved to be used for up to 6 days in continuous subcutaneous insulin infusion (CSII). In addition, aspart has been evaluated in all types of patient populations and has been approved for pediatric patients older than 2 years old and, specifically, in patients under CSII therapy." @default.
- W2024338403 created "2016-06-24" @default.
- W2024338403 creator A5018064279 @default.
- W2024338403 date "2012-06-01" @default.
- W2024338403 modified "2023-09-27" @default.
- W2024338403 title "Aspectos básicos de la insulina aspart: ventajas potenciales derivadas de su mayor estabilidad fisicoquímica" @default.
- W2024338403 cites W1537816584 @default.
- W2024338403 cites W1752045965 @default.
- W2024338403 cites W1810520060 @default.
- W2024338403 cites W1964029624 @default.
- W2024338403 cites W1964327205 @default.
- W2024338403 cites W1965568752 @default.
- W2024338403 cites W1976763650 @default.
- W2024338403 cites W1979889837 @default.
- W2024338403 cites W2002371885 @default.
- W2024338403 cites W2014259263 @default.
- W2024338403 cites W2045262199 @default.
- W2024338403 cites W2056175959 @default.
- W2024338403 cites W2058804545 @default.
- W2024338403 cites W2065565878 @default.
- W2024338403 cites W2074628239 @default.
- W2024338403 cites W2078089300 @default.
- W2024338403 cites W2081528927 @default.
- W2024338403 cites W2091336973 @default.
- W2024338403 cites W2106582738 @default.
- W2024338403 cites W2123165496 @default.
- W2024338403 cites W2126781806 @default.
- W2024338403 cites W2139378297 @default.
- W2024338403 cites W2145012784 @default.
- W2024338403 cites W2148213185 @default.
- W2024338403 cites W2149194615 @default.
- W2024338403 cites W2150939399 @default.
- W2024338403 cites W2153701071 @default.
- W2024338403 cites W2171294019 @default.
- W2024338403 cites W2331389797 @default.
- W2024338403 cites W2337454357 @default.
- W2024338403 cites W2586645431 @default.
- W2024338403 cites W2769264260 @default.
- W2024338403 doi "https://doi.org/10.1016/s1134-3230(12)70018-2" @default.
- W2024338403 hasPublicationYear "2012" @default.
- W2024338403 type Work @default.
- W2024338403 sameAs 2024338403 @default.
- W2024338403 citedByCount "0" @default.
- W2024338403 crossrefType "journal-article" @default.
- W2024338403 hasAuthorship W2024338403A5018064279 @default.
- W2024338403 hasConcept C142362112 @default.
- W2024338403 hasConcept C15708023 @default.
- W2024338403 hasConcept C71924100 @default.
- W2024338403 hasConceptScore W2024338403C142362112 @default.
- W2024338403 hasConceptScore W2024338403C15708023 @default.
- W2024338403 hasConceptScore W2024338403C71924100 @default.
- W2024338403 hasLocation W20243384031 @default.
- W2024338403 hasOpenAccess W2024338403 @default.
- W2024338403 hasPrimaryLocation W20243384031 @default.
- W2024338403 hasVolume "28" @default.
- W2024338403 isParatext "false" @default.
- W2024338403 isRetracted "false" @default.
- W2024338403 magId "2024338403" @default.
- W2024338403 workType "article" @default.